Elevance Health, Inc. $ELV Shares Sold by Mcdonald Capital Investors Inc. CA

Mcdonald Capital Investors Inc. CA decreased its stake in Elevance Health, Inc. (NYSE:ELV) by 32.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,608 shares of the company’s stock after selling 4,541 shares during the period. Elevance Health accounts for 0.2% of Mcdonald Capital Investors Inc. CA’s investment portfolio, making the stock its 18th largest holding. Mcdonald Capital Investors Inc. CA’s holdings in Elevance Health were worth $3,105,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Elevance Health by 0.6% in the third quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock valued at $7,431,322,000 after acquiring an additional 141,747 shares in the last quarter. Sanders Capital LLC increased its position in shares of Elevance Health by 24.7% during the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock worth $2,265,773,000 after purchasing an additional 1,152,440 shares in the last quarter. Artisan Partners Limited Partnership lifted its holdings in shares of Elevance Health by 9.7% in the 2nd quarter. Artisan Partners Limited Partnership now owns 3,675,179 shares of the company’s stock valued at $1,429,498,000 after purchasing an additional 324,399 shares during the last quarter. Norges Bank acquired a new stake in shares of Elevance Health in the 2nd quarter valued at about $1,148,379,000. Finally, Massachusetts Financial Services Co. MA boosted its position in shares of Elevance Health by 4.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,440,630 shares of the company’s stock valued at $788,616,000 after purchasing an additional 112,020 shares during the period. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Stock Down 1.5%

Shares of NYSE:ELV opened at $342.95 on Monday. The company has a market cap of $75.69 billion, a price-to-earnings ratio of 13.65, a PEG ratio of 1.90 and a beta of 0.50. The firm’s 50-day simple moving average is $352.37 and its 200-day simple moving average is $334.71. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $458.75.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. During the same period in the prior year, the company posted $3.84 earnings per share. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities research analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. Elevance Health’s dividend payout ratio (DPR) is presently 27.23%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ELV. Royal Bank Of Canada downgraded Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective for the company. in a report on Tuesday, February 3rd. Truist Financial decreased their price target on shares of Elevance Health from $400.00 to $390.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. JPMorgan Chase & Co. lifted their price objective on shares of Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Weiss Ratings cut shares of Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, February 2nd. Finally, Wolfe Research set a $425.00 target price on shares of Elevance Health and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Twelve equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Elevance Health currently has a consensus rating of “Moderate Buy” and an average price target of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.